TABLE 2

Pharmacokinetic parameters in wild-type mice

The values were larger than the half-life in plasma because the complete elimination phase was not captured in the experiments.

	Unit	AEE788	Afatinib	AZD3759	Dacomitinib	Erlotinib	Gefitinib	Osimertinib	Vandetanib
t_half	h	12.4	7.20	2.37	8.45	0.827	2.66	2.77	13.7
Apparent CL	ml/h/kg	582	1196	1915	881	961	1706	1407	250
Apparent V_d	ml/kg	10,377	12,389	6539	10,723	1146	6542	5632	4947
t_{half, brain}	h	13.9	25.7^{^a}	2.69	10.5	0.75	14.2^{^a}	2.27	10.6
AUC_{last, plasma}	h*ng/ml	985	734	486	826	1001	576	645	2230
S.E._AUC_{last, plasma}	h*ng/ml	23.3	80.6	27.7	79.2	39.6	54.6	43.7	61.3
AUC_{last, brain}	h*ng/ml	65.3	186	828	505	62.4	206	638	1416
S.E._AUC_{last, brain}	h*ng/ml	2.20	3.35	60.8	24.0	8.21	3.85	31.9	95.0

Apparent CL, apparent clearance (CL/F); Apparent V_d, apparent volume of distribution (V_d/F); AUC_{last, brain}, area under the curve from zero to the time of last measured concentration in brain; AUC_{last, plasma}, area under the curve from zero to the time of last measured concentration in plasma; S.E._AUC_{last, brain}, standard error of an estimate of area under the curve in brain; S.E._AUC_{last, plasma}, standard error of an estimate of area under the curve in plasma; t_half, half-life of a drug in plasma; t_{half, brain}, half-life of a drug in brain.
↵^a The half-life was determined by the slope of last three time points in concentration-time profile.